- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01967329
CANHelp Working Group Treatment Trials
Canadian North Helicobacter Pylori (CANHelp) Working Group Treatment Trials
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The CANHelp Working Group is a collaborative team that links University of Alberta researchers with Canadian northern community leaders and health officials in a collaborative effort to investigate H. pylori infection with the goal of finding solutions to community concerns about health risks. The research program uses a community-driven research approach in northern communities to characterize the burden of disease from H. pylori infection and exchange knowledge with community members and decision makers to identify ways to reduce health risks from this infection.
For the participating communities, the treatment trials aim to:
- Estimate the effectiveness of alternate H. pylori treatment regimens to identify optimal regimens for the local setting
- Identify factors external to the treatment regimen that influence short- and long-term treatment success
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2E1
- University of Alberta
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Over 15 years of age
- Identified as H. pylori infected with a positive urea breath test and/or biopsy-based evidence of H. pylori infection
Exclusion Criteria:
- Allergy to amoxicillin, metronidazole or clarithromycin
- Antibiotic therapy within 4 weeks prior to randomization
- Pregnant or breastfeeding
- Severe cardio-respiratory, pulmonary, endocrine, hepatic or renal disease
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Standard Triple, treatment naive
Standard Triple Therapy for H. pylori: Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg) One of two treatments randomly assigned to treatment naive participants in Aklavik |
Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
Altri nomi:
|
Comparatore attivo: Sequential, treatment naive
Sequential Therapy for H. pylori: Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg) One of two treatments randomly assigned to treatment naive participants in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson |
Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
Altri nomi:
|
Comparatore attivo: Quadruple, treatment naive
Quadruple Thearpy for H. pylori: Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily One of two treatments randomly assigned to treatment naive participants in Old Crow, Tuktoyaktuk & Fort McPherson |
Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
Altri nomi:
|
Comparatore attivo: Sequential, previous failure(s)
Sequential Therapy for H. pylori: Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg) One of two treatments randomly assigned to participants who previously failed one or more treatments in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson |
Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
Altri nomi:
|
Comparatore attivo: Quadruple, previous failure(s)
Quadruple Therapy for H. pylori: Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily One of two treatments randomly assigned to participants who previously failed treatment in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson |
Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
Altri nomi:
|
Comparatore attivo: Sequential, clarithromycin-resistant
Sequential Therapy for H. pylori: Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg) One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik |
Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
Altri nomi:
|
Comparatore attivo: Quadruple, clarithromycin-resistant
Quadruple Therapy for H. pylori: Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik |
Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Post-treatment H. pylori status by urea breath test
Lasso di tempo: A minimum of 10 weeks after participant has completed treatment
|
Treatment effectiveness, defined as the probability (average risk) of elimination of H. pylori infection following treatment, measured as the proportion of trial participants with a negative post-treatment urea breath test at least 10 weeks following completion of treatment. Using an intention-to-treat analysis, the denominator for this proportion is the number of trial participants assigned treatment. Using a per-protocol analysis, the denominator for this proportion is the number of trial participants who completed treatment and were tested post-treatment. Participants are administered a urea breath test using 13C-labeled urea dissolved in a citric acid solution. We use the following test value classifications for determining the outcome: >=4.0 (Positive for H. pylori infection) Between 2.5 and 4.0 (Borderline; repeat test) Between 2.4 and -1.99 (Negative for H. pylori infection) Less than -2.0 (Uncertain test result, repeat test) |
A minimum of 10 weeks after participant has completed treatment
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Adherence to treatment regimen
Lasso di tempo: An expected average of 1 week after treatment is completed
|
Participants are asked to return blister packs with unused medication so skipped doses can be counted.
Participants are also interviewed to obtain details about their adherence to the regimen.
|
An expected average of 1 week after treatment is completed
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Frequency of adverse effects
Lasso di tempo: From the time treatment is started to an expected average of 1 week after treatment is completed
|
Participants are contacted by telephone during the completion of the treatment regimen and asked if they have experienced adverse effects.
Participants are also interviewed immediately after the completion of treatment and asked if they experienced adverse effects during the completion of treatment.
|
From the time treatment is started to an expected average of 1 week after treatment is completed
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Karen Goodman, PhD, University of Alberta
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- Pro00007868
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Infezione da Helicobacter Pylori
-
ImevaXCompletatoSoggetti infetti da Helicobacter Pylori | Helicobacter Pylori Soggetti ingenuiGermania
-
Statistical Center, NTUHCTCTaiwan Sugar Cooperation CompanyCompletato
-
TakedaCompletato
-
Fu Jen Catholic University HospitalAttivo, non reclutanteHelicobacter pyloriTaiwan
-
Poitiers University HospitalCompletato
-
Shandong UniversitySconosciutoHelicobacter pyloriCina
-
TakedaCompletato
-
Hamamatsu UniversityOita UniversitySconosciutoHelicobacter pyloriGiappone
-
National Liver Institute, EgyptFuture pharmaceutical industriesReclutamentoHelicobacter pyloriEgitto
-
Hillel Yaffe Medical CenterNon ancora reclutamento
Prove cliniche su Standard Triple
-
University of PennsylvaniaRestaurant AssociatesAttivo, non reclutanteObesità | Aumento di peso | Preferenze alimentari | Selezione del ciboStati Uniti
-
HealthpointCompletato
-
Neuroscience Trials AustraliaNational Institute for Health Research, United Kingdom; Northern Ireland Chest... e altri collaboratoriCompletato
-
University of MichiganIscrizione su invitoDepressione | Ansia | Disturbi del sonno | DipendenzaStati Uniti
-
Nantes University HospitalMinistry of Health, France; University Hospital, ToursCompletatoShock | Malattia critica | Malattia critica miopatia | Ventilazione meccanica | Infezione nosocomialeFrancia, Guadalupa
-
University of Missouri-ColumbiaCompletatoLombalgia | Dolore pelvico | Adesioni | Tessuto cicatrizialeStati Uniti
-
Institute of Cardiology, Warsaw, PolandSconosciutoRiabilitazione cardiologicaPolonia
-
Avita MedicalNAMSACompletatoUlcere venose delle gambeRegno Unito, Francia
-
University of MichiganCompletatoFibromialgia | FibrositeStati Uniti
-
University of OklahomaNational Cancer Institute (NCI)CompletatoSmettere di fumareStati Uniti